Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Asset Writedowns and Impairment (2024 - 2025)

Foghorn Therapeutics has reported Asset Writedowns and Impairment over the past 2 years, most recently at $5.9 million for Q4 2025.

  • Quarterly results put Asset Writedowns and Impairment at $5.9 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $5.9 million (up 146.62% YoY), and the annual figure for FY2025 was $5.9 million, up 146.62%.
  • Asset Writedowns and Impairment for Q4 2025 was $5.9 million at Foghorn Therapeutics, up from $2.4 million in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for FHTX hit a ceiling of $5.9 million in Q4 2025 and a floor of $2.4 million in Q2 2024.